Ionpath

As the pioneer in high-definition spatial proteomics, Ionpath is revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry (IHC), enabling a deeper understanding of the tissue microenvironment with highly multiplexed—quantitative and spatial—single-cell phenotype analysis. MIBI uniquely provides actionable information, delivering novel insights into disease state, mechanism of action, and patient response with clinical-grade reproducibility.

Using MIBI-enabled high-definition spatial proteomics, 40+ protein markers can be visualized simultaneously – providing the multiplex power needed for enumerating cell populations and the immune infiltrate within tissue microenvironments, as well as, for quantifying expression of checkpoints and other key proteins with spatial context. In addition, MIBI data allows spatial analyses such as mapping of cellular neighborhoods and tumor-immune boundaries.

With MIBI technology and the expertise of its world-class pathology and data science teams, Ionpath delivers actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research.